In the unprecedented move announced in the 2024-25 Mid-Year Economic and Fiscal Outlook, the copy recommended by the Medical Services Advisory Committee would be funded despite no evaluation or approval by the Therapeutic Goods Administration. …
Novartis joins legal action against unapproved copy of radioligand therapy
February 25, 2025 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The George Institute welcomes new international push to raise the bar on migraine
February 26, 2025 - - Latest News -
Health department to front Senate Estimates for final pre-election hearing
February 26, 2025 - - Latest News -
New whitepaper reveals strategies to manage salary trends revealed in report
February 25, 2025 - - Latest News -
Election could be the circuit-breaker opportunity to 'recharge' reform
February 25, 2025 - - Latest News -
Novartis joins legal action against unapproved copy of radioligand therapy
February 25, 2025 - - Latest News -
Orthocell submits for Remplir regulatory approval in Thailand
February 24, 2025 - - Australian Biotech -
AdPha welcomes commitment to expand access to bulk-billing incentive
February 24, 2025 - - Latest News